Melanoma News and Research

Latest Melanoma News and Research

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.

21 May 2010

European researchers define research priorities in biogerontology

The quality of the medical care for geriatric patients is a major investment for society and must imperatively be a research priority in Europe. This is why 50 European researchers, met on May 17 - 19 in Brussels, to define the research priorities in the field of biogerontology for the next 10 to 15 years.

21 May 2010

Cancer Institute of New Jersey investigators target autophagy

In an effort to improve current anticancer treatments, investigators at The Cancer Institute of New Jersey (CINJ) have been targeting a process known as autophagy, in which cancer cells eat themselves as a measure of self preservation under chemotherapy and radiation stress, thus prolonging tumor cell survival and inducing resistance to therapy.

21 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.

21 May 2010

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

21 May 2010

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.

21 May 2010

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Antigenics today announced that data from a multi-center Phase 1/2 clinical trial of Oncophage (vitespen) for recurrent high-grade glioma (brain cancer) was presented at the International Conference on Brain Tumor Research and Therapy. The study was conducted by the Brain Tumor Research Center at the University of California, San Francisco.

20 May 2010

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

The type and quality of care and services to ensure a cancer patient dies with dignity in the setting of their choice depends on where the person lives in Canada, according to a special report about end-of-life care in Canadian Cancer Statistics 2010, released today by the Canadian Cancer Society.

20 May 2010

Canadian Cancer Society advocates for greater access to quality palliative care

Cancer is the leading cause of death in Canada, making end-of-life care a growing concern as the population ages. This year's annual Canadian Cancer Statistics report, released by the Canadian Cancer Society, highlights the often heartbreaking challenges faced by dying cancer patients and their friends and family members who often take on the role of caregivers.

20 May 2010

Tanning an addiction among young women

Amber Peterson, 31, used to visit tanning booths every other day for 10 years until she was diagnosed with the deadliest form of skin cancer at age 26. After surgery to remove the melanoma and several lymph nodes, this blond-haired, blue-eyed, fair-skinned woman is currently cancer-free. She has since traded in tanning beds for self-tanner in a bottle.

19 May 2010

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Oncolytics Biotech Inc. announced today that a paper entitled "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," has been published in the online version of the journal Clinical Cancer Research.

19 May 2010

Warnings about a ruined appearance is best way to reduce tanning salon visits

What's the most effective way to convince young women to cut back on their indoor tanning, a habit that hikes their risk of melanoma, the deadliest form of skin cancer, by 75 percent? Warn them that it will cause leathery, wrinkled skin.

18 May 2010

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects. Unmet needs of patients, especially those with advanced melanoma are therefore quite high and have led to a low drug adoption and market growth over the years. The future looks brighter though, with a few promising drugs in pipeline for advanced melanoma.

18 May 2010

Cancer Research UK launches new cancer centre in Leeds

LEEDS today joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

18 May 2010

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

17 May 2010

Large number of people do not see health-care provider for skin cancer screening: Survey

Despite the fact that skin cancer is the only cancer that can be seen on the surface of the skin, a new survey by the American Academy of Dermatology reports that a large number of people are not taking the time to examine their skin for any changes that could be warning signs of skin cancer or seeing a health-care provider for a skin cancer screening.

17 May 2010

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

Saint John's Health Center Trustee and philanthropist Patrick Soon-Shiong, M.D., who developed the first FDA-approved protein nanoparticle treatment for cancer, has received the 2010 Distinguished Medical Science Award from the Friends of the National Library of Medicine for his significant contributions to the research and treatment of diabetes and cancer.

15 May 2010

3D test for diagnosing malignant melanoma

UK scientists have developed a 3D test for malignant melanoma that can identify problems not easily spotted in a standard two-dimensional view of the pattern on the skin. The researchers describe the technique in detail in the latest issue of the International Journal of Modelling, Identification and Control.

14 May 2010

Melanoma News and Research

Latest Melanoma News and Research

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

European researchers define research priorities in biogerontology

Cancer Institute of New Jersey investigators target autophagy

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

Canadian Cancer Society advocates for greater access to quality palliative care

Tanning an addiction among young women

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Warnings about a ruined appearance is best way to reduce tanning salon visits

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

Cancer Research UK launches new cancer centre in Leeds

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Large number of people do not see health-care provider for skin cancer screening: Survey

Saint John's Health Center Trustee receives 2010 Distinguished Medical Science Award

3D test for diagnosing malignant melanoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Melanoma News and Research

Latest Melanoma News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in